Skip to main content
Triangle logo TriangleCheck this trial

177Lu-PSMA-617

177Lu-PSMA-617 in People With Gliomas

  • RegistryNCT07223034
  • PhasePhase 1
  • StatusRecruiting
  • ConditionGlioma
  • SponsorMemorial Sloan Kettering Cancer Center
How 177Lu-PSMA-617 works1 min

The drug

What is being tested.

This agent will be given for 2-6 total doses, spaced 4 weeks (+/-1 week) apart. This will be administered on the 2nd day of the first two cycles of SOC adjuvant temozolomide.

Patients will begin taking Temozolomide orally on the first 5 days of each 28-day cycle. The first dose will be given the evening before the first infusion of 177Lu-PSMA- 617.

The study

How the trial runs.

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Confirmed histologic diagnosis of a WHO grade 2-4 glioma that is IDH1 R132H-wildtype, including the following:
  • Diffuse astrocytoma, IDH-wildtype (grade 2-4)
  • Glioblastoma, IDH-wildtype
  • Diffuse midline glioma, H3 K27-altered
  • Diffuse hemispheric glioma, H3 G34-mutant
  • Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype PSMA positive pathological stain (by immunohistochemistry) of baseline (pre-radiotherapy) resection or biopsy sample

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.

Not sure whether you would qualify?

Would this trial apply to me?

7-day free trial, then $9 a month. Cancel anytime.

More in Brain and CNSBrowse Brain and CNS →

Glioblastoma Multiforme of BrainNCT06815432

15.GPC3-CAR T cells

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

Baylor College of MedicineOpen the brief

EGFR-Altered IDH-Wildtype Glioblastoma or GliosarcomaNCT07089641

EGFR Inhibitor ERAS-801

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Jonsson Comprehensive Cancer CenterOpen the brief

Currently Only Enrolling Glioblastoma Patients at First RecurrenceNCT05139056

Neural Stem Cells-expressing CRAd-S-pk7

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

City of Hope Medical CenterOpen the brief